[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100353124":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":16,"studyPopulation":19,"armGroups":20,"interventions":26,"overallOfficials":16,"centralContacts":32,"locations":41,"responsibleParty":113,"collaborators":115,"id":118,"slug":16,"hasResults":119,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":16,"eligibilityCriteria":123,"healthyVolunteers":119,"sex":124,"minAge":125,"maxAge":16,"enrollmentInfo":126,"targetDuration":16,"studyType":129,"phases":16,"briefSummary":130,"conditions":131,"keywords":16,"overallStatus":58,"whyStopped":16,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},{"fullName":5,"class":6},"Allarity Therapeutics","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":16},[9],{"measure":10,"description":11,"timeFrame":12},"Identification of ovarian cancer patients with high likelihood of being sensitive to investigational cancer drug","based on FFPE ovarian cancer tissue","up to 2 years",[14],{"measure":15,"description":16,"timeFrame":12},"Retrospective analysis of whether or not the DRP method can predict and confirm the obtained sensitivity to the prior drugs used in the treatment of ovarian cancer",null,{"allocation":16,"interventionModel":16,"interventionModelDescription":16,"primaryPurpose":16,"observationalModel":18,"timePerspective":18,"maskingInfo":16},"OTHER","Patients will be identified at their already planned treatment and or at control visits at the oncology department",[21],{"label":22,"type":16,"description":23,"interventionNames":24},"Ovarian cancer patients","with formalin-fixed paraffin-embedded (FFPE) tumor tissue available",[25],"Device: Drug Response Predictor® (DRP)",[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":16},"DEVICE","Drug Response Predictor® (DRP)","A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.",[22],[33,38],{"name":34,"role":35,"phone":36,"phoneExt":16,"email":37},"US: Kathleen Moore","CONTACT","+1 405-271-8707","KathleenMoore@ouhealth.com",{"name":39,"role":35,"phone":16,"phoneExt":16,"email":40},"Europe: Rebecca Kristeleit","Rebecca.Kristeleit@gstt.nhs.uk",[42,56,75,92,105],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":16},"Dana-Farber Cancer Institute","COMPLETED","Boston","Massachusetts","02215","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-71.05977,42.35843,{"lat":54,"lon":53},{"facility":57,"status":58,"city":59,"state":60,"zip":61,"country":48,"countryCode":49,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"OU Health Stephenson Cancer Center","RECRUITING","Oklahoma City","Oklahoma","73104",{"type":51,"coordinates":63},[64,65],-97.51643,35.46756,{"lat":65,"lon":64},[68,72],{"name":69,"role":35,"phone":70,"phoneExt":16,"email":71},"Christine Pappaterra, RN","405-271-8707","Christine-Pappaterra@ouhsc.edu",{"name":73,"role":74,"phone":16,"phoneExt":16,"email":16},"Kathleen Moore, MD","PRINCIPAL_INVESTIGATOR",{"facility":76,"status":58,"city":77,"state":78,"zip":79,"country":48,"countryCode":49,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Swedish Center for Research and Innovation","Seattle","Washington","98122",{"type":51,"coordinates":81},[82,83],-122.33207,47.60621,{"lat":83,"lon":82},[86,90],{"name":87,"role":35,"phone":88,"phoneExt":16,"email":89},"Karina Sills","206-386-2227","karina.sills@swedish.org",{"name":91,"role":74,"phone":16,"phoneExt":16,"email":16},"Fernanda Baptista Musa, MD",{"facility":93,"status":94,"city":95,"state":96,"zip":97,"country":98,"countryCode":99,"cosmosGeoPoint":100,"geoPoint":104,"contacts":16},"Beatson West of Scotland Cancer Centre","ACTIVE_NOT_RECRUITING","Glasgow","Scotland","G12 0YN","United Kingdom","UK",{"type":51,"coordinates":101},[102,103],-4.25763,55.86515,{"lat":103,"lon":102},{"facility":106,"status":94,"city":107,"state":16,"zip":16,"country":98,"countryCode":99,"cosmosGeoPoint":108,"geoPoint":112,"contacts":16},"Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital","London",{"type":51,"coordinates":109},[110,111],-0.12574,51.50853,{"lat":111,"lon":110},{"type":114,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR",[116],{"name":117,"class":18},"Amarex Clinical Research","100353124",false,"NCT03877796","Clinical Pre-screening Protocol for Ovarian Cancer","Development of Drug Response Predictor (DRP) to Test Sensitivity to Investigational Anti-Cancer Drugs in Patients With Advanced Ovarian Cancer","Inclusion Criteria:\n\n* Patients with histological confirmed epithelia ovarian cancer\n* Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible.\n* Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting\n* FFPE tumor tissue available\n\nExclusion Criteria:\n\n* Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy.\n* Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator","FEMALE","18 Years",{"count":127,"type":128},60,"ESTIMATED","OBSERVATIONAL","The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.",[132],"Ovarian Cancer","2025-10-28",{"date":135,"type":136},"2025-10-30","ACTUAL",{"date":138,"type":136},"2019-04-11",{"date":140,"type":128},"2026-12",{"name":5,"class":6},5]